Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah McGlasson

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nature Reviews. Neurology|August 26, 2015
Type I interferon dysregulation and neurological diseaseSarah McGlasson, Alexa Jury, Andrew Jackson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 25, 2019
Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studiesSarah-Jane Martin, Sarah McGlasson, David Hunt, et al.
Frontiers in Immunology|June 22, 2018
Neurological Disease in Lupus: Toward a Personalized Medicine ApproachSarah McGlasson, Stewart Wiseman, Joanna Wardlaw, et al.
Wellcome Open Research|June 10, 2024
Phenotypes associated with genetic determinants of type I interferon regulation in the UK Biobank: a protocolBastien Rioux, Michael Chong, Rosie Walker, et al.
Nature Communications|January 27, 2026
Oligoprotein type I interferon signatures, but not TREX1 variants, increase risk of systemic lupus erythematosus in UK BiobankBastien Rioux, Sarah McGlasson, Deborah Forbes, et al.
Wellcome Open Research|February 2, 2018
Rare variants of the 3'-5' DNA exonuclease <i>TREX1</i> in early onset small vessel strokeSarah McGlasson, Kristiina Rannikmäe, Steven Bevan, et al.
Brain : a Journal of Neurology|June 6, 2025
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel diseaseSarah McGlasson, Katy Reid, Anna Klingseisen, et al.
Immunity|June 15, 2024
The brain microvasculature is a primary mediator of interferon-α neurotoxicity in human cerebral interferonopathiesBarney Viengkhou, Emina Hayashida, Sarah McGlasson, et al.
The Lancet. Rheumatology|July 2, 2026
Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine studyDeborah Forbes, Ivana Jorgacevic, Jessica Tarn, et al.
Blood|September 25, 2016
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculatureDavid Kavanagh, Sarah McGlasson, Alexa Jury, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nature Reviews. Neurology|August 26, 2015
Type I interferon dysregulation and neurological diseaseSarah McGlasson, Alexa Jury, Andrew Jackson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 25, 2019
Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studiesSarah-Jane Martin, Sarah McGlasson, David Hunt, et al.
Frontiers in Immunology|June 22, 2018
Neurological Disease in Lupus: Toward a Personalized Medicine ApproachSarah McGlasson, Stewart Wiseman, Joanna Wardlaw, et al.
Wellcome Open Research|June 10, 2024
Phenotypes associated with genetic determinants of type I interferon regulation in the UK Biobank: a protocolBastien Rioux, Michael Chong, Rosie Walker, et al.
Nature Communications|January 27, 2026
Oligoprotein type I interferon signatures, but not TREX1 variants, increase risk of systemic lupus erythematosus in UK BiobankBastien Rioux, Sarah McGlasson, Deborah Forbes, et al.
Wellcome Open Research|February 2, 2018
Rare variants of the 3'-5' DNA exonuclease <i>TREX1</i> in early onset small vessel strokeSarah McGlasson, Kristiina Rannikmäe, Steven Bevan, et al.
Brain : a Journal of Neurology|June 6, 2025
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel diseaseSarah McGlasson, Katy Reid, Anna Klingseisen, et al.
Immunity|June 15, 2024
The brain microvasculature is a primary mediator of interferon-α neurotoxicity in human cerebral interferonopathiesBarney Viengkhou, Emina Hayashida, Sarah McGlasson, et al.
The Lancet. Rheumatology|July 2, 2026
Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine studyDeborah Forbes, Ivana Jorgacevic, Jessica Tarn, et al.
Blood|September 25, 2016
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculatureDavid Kavanagh, Sarah McGlasson, Alexa Jury, et al.
Pageof 2